1 |
Payeras MR, Cherubini K, Figueiredo MA, et al. Oral lichen planus: focus on etiopathogenesis[J]. Arch Oral Biol, 2013, 58(9): 1057-1069.
|
2 |
Maymone MBC, Greer RO, Kesecker J, et al. Premalignant and malignant oral mucosal lesions: clinical and pathological findings[J]. J Am Acad Dermatol, 2019, 81(1): 59-71.
|
3 |
Carrozzo M, Porter S, Mercadante V, et al. Oral lichen planus: a disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies[J]. Periodontol 2000, 2019, 80(1): 105-125.
|
4 |
Nogueira PA, Carneiro S, Ramos-e-Silva M. Oral lichen planus: an update on its pathogenesis[J]. Int J Dermatol, 2015, 54(9): 1005-1010.
|
5 |
Ichimura M, Hiratsuka K, Ogura N, et al. Expression profile of chemokines and chemokine receptors in epithelial cell layers of oral lichen planus[J]. J Oral Pathol Med, 2006, 35(3): 167-174.
|
6 |
Scheu S, Ali S, Ruland C, et al. The C-C chemokines CCL17 and CCL22 and their receptor CCR4 in CNS autoimmunity[J]. Int J Mol Sci, 2017, 18(11): 2306.
|
7 |
Marshall A, Celentano A, Cirillo N, et al. Tissue-specific regulation of CXCL9/10/11 chemokines in keratinocy-tes: implications for oral inflammatory disease[J]. PLoS One, 2017, 12(3): e0172821.
|
8 |
Antonelli A, Ferrari SM, Giuggioli D, et al. Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases[J]. Autoimmun Rev, 2014, 13(3): 272-280.
|
9 |
Flier J, Boorsma DM, van Beek PJ, et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation[J]. J Pathol, 2001, 194(4): 398-405.
|
10 |
Ruland C, Renken H, Kuzmanov I, et al. Chemokine CCL17 is expressed by dendritic cells in the CNS during experimental autoimmune encephalomyelitis and promo-tes pathogenesis of disease[J]. Brain Behav Immun, 2017, 66: 382-393.
|
11 |
Fang J, Wang C, Shen C, et al. The expression of CXCL10/CXCR3 and effect of the axis on the function of T lymphocyte involved in oral lichen planus[J]. Inflammation, 2019, 42(3): 799-810.
|
12 |
Shan J, Shen C, Fang J, et al. Potential roles of the CCL17-CCR4 axis in immunopathogenesis of oral lichen planus[J]. J Oral Pathol Med, 2020, 49(4): 328-334.
|
13 |
van der Meij EH, van der Waal I. Lack of clinicopathologic correlation in the diagnosis of oral lichen planus based on the presently available diagnostic criteria and suggestions for modifications[J]. J Oral Pathol Med, 2003, 32(9): 507-512.
|
14 |
Ferri EP, Gallo CB, Abboud CS, et al. Efficacy of photobiomodulation on oral lichen planus: a protocol study for a double-blind, randomised controlled clinical trial[J]. BMJ Open, 2018, 8(10): e024083.
|
15 |
Richmond JM, Strassner JP, Essien KI, et al. T-cell positioning by chemokines in autoimmune skin diseases[J]. Immunol Rev, 2019, 289(1): 186-204.
|
16 |
Matsuo K, Hatanaka S, Kimura Y, et al. A CCR4 antagonist ameliorates atopic dermatitis-like skin lesions induced by dibutyl phthalate and a hydrogel patch contai-ning ovalbumin[J]. Biomed Pharmacother, 2019, 109: 1437-1444.
|
17 |
Bertolini TB, Piñeros AR, Prado RQ, et al. CCR4-dependent reduction in the number and suppressor function of CD4+Foxp3+ cells augments IFN-γ-mediated pulmonary inflammation and aggravates tuberculosis pathogenesis[J]. Cell Death Dis, 2018, 10(1): 11.
|
18 |
Moriyama M, Hayashida JN, Toyoshima T, et al. Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren's syndrome[J]. Clin Exp Immunol, 2012, 169(1): 17-26.
|
19 |
Hayashida JN, Nakamura S, Toyoshima T, et al. Possible involvement of cytokines, chemokines and chemokine receptors in the initiation and progression of chronic GVHD[J]. Bone Marrow Transplant, 2013, 48(1): 115-123.
|